Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Aubier, R. Buhl, J. Haughney, J. Ostinelli, T. Ekström, L. Jörgensen, O. C. P. van Schayck (Paris, Rueil-Malmaison, France; , Germany; Aberdeen, United Kingdom; Södertälje, Sweden; , Netherlands). Predictive factors for asthma control according to ACQ₅ in asthma patients treated with budesonide/formoterol maintenance and reliever therapy. Results from the EuroSMART study. Eur Respir J 2010; 36: Suppl. 54, 4577

Member's Comments

No comment yet.

Related content which might interest you: Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Stability of overall asthma control achieved with budesonide/formoterol maintenance + reliever therapy Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Assessing overall asthma control with budesonide/formoterol maintenance + relief in moderate/severe asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Efficacy of budesonide/formoterol maintenance and reliever therapy in mild asthma Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017 Preventing asthma exacerbations with budesonide/formoterol maintenance + relief: a pooled analysis Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Intermittent therapy with budesonide/formoterol in children with moderate asthma. Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 616s Year: 2007 Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Variation of regular maintenance therapy with budesonide/formoterol of children with asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001 High or standard initial dose of budesonide to control mild-to-moderate asthma? Source: Eur Respir J 2001; 17: 856-862 Year: 2001 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma Source: Eur Respir J, 51 (1) 1701688; 10.1183/13993003.01688-2017 Year: 2018